Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Deutsche Bank analyst James Shin maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...

The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...

By Dani Blum The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.